U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
of 1934
Date of
Report (Date of earliest event reported): November 18,
2016
HH BIOTECHNOLOGY HOLDINGS COMPANY
(Exact
name of registrant as specified in its charter)
0-23015
(Commission
File No.)
|
Nevada
(State
or other jurisdiction of
incorporation
or organization)
|
87-0450232
(IRS
Employer Identification No.)
|
C Site 25-26F President Building, No. 69 Heping North
Street
Heping District, Shenyang 110003, Peoples Republic of
China
(Address
of principal executive offices)
0086-24-22813888
(Registrant’s
telephone number)
Not applicable
(Former
Name or Former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
November 18, 2016, the Board of Directors of HH Biotechnology
Holdings Company (the “Company”) adopted resolutions
increasing the number of directors on the board to five and
electing Mr. Charles T. Mathews as a director to fill the new
directorship, and Mr. Mathews was assigned as the chairman of the
Compensation Committees of the Board of Directors of the
Company.
For
service on the Board, Mr. Mathews will receive a quarterly fee of
$10,000 and reimbursement of expenses.
SIGNATURES
Pursuant to the
requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
HH
Biotechnology Holdings Company
|
|
|
|
|
|
|
|
|
Date: November 21,
2016
|
By:
|
/s/
Sheng
Jiang
|
|
|
|
|
Sheng
Jiang
|
|
|
|
|
Chief Executive
Officer
|
|